Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 8.14B 1.22B 1.08B 1.01B 919M 1.72B 117B 1.75B 12.18B 4.72B 59.61B 4.56B 4.46B 192B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 7.3B 1.09B 968M 904M 824M 1.55B 105B 1.57B 10.93B 4.23B 53.47B 4.09B 4B 172B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.63%
Yield 2024 *
-
Yield 2025 -
08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-14 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-15 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
25-10-28 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-04 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
25-05-27 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25-04-25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
25-03-14 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
25-03-12 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
25-03-10 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day+5.19%
1 week+0.27%
1 month-16.48%
3 months+35.19%
6 months+4.89%
Current year+18.89%
1 week 3.38
Extreme 3.38
3.76
1 month 3.3
Extreme 3.3
4.75
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 2022-12-25
Corporate Officer/Principal 42 2018-04-17
Corporate Officer/Principal 40 2019-05-22
Director TitleAgeSince
Director/Board Member 40 2025-03-13
Director/Board Member 53 2022-11-10
Director/Board Member 42 2022-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/25 Sell 587,500 0.0283%
7/2/25 Sell

Director

259,600 0.0125%
7/2/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+5.19%+0.27%+18.12%+61.50% 1.21B
-0.62%-0.10%+50.70%+114.07% 1,031B
-2.30%-3.90%+39.50%+66.07% 638B
-0.63%-1.94%+12.26%+74.38% 462B
-1.03%-2.88%+71.35%+39.69% 359B
-0.03%-3.91%+34.28%+39.35% 335B
-1.58%+0.39%+17.92%+25.77% 273B
-2.02%-3.20%+7.60%+8.38% 253B
-3.38%+0.29%+44.32%+51.54% 228B
-1.04%-2.56%+32.88%+96.82% 185B
Average -0.14%-0.30%+32.89%+57.76% 376.51B
Weighted average by Cap. -0.32%-0.35%+38.04%+69.18%

Financials

2024 2025
Net sales 2.44B 364M 324M 302M 276M 517M 35.09B 526M 3.65B 1.42B 17.88B 1.37B 1.34B 57.59B 2.14B 319M 283M 264M 241M 452M 30.7B 460M 3.2B 1.24B 15.64B 1.2B 1.17B 50.39B
Net income 233M 34.75M 30.85M 28.82M 26.28M 49.31M 3.35B 50.14M 348M 135M 1.7B 130M 128M 5.49B 377M 56.27M 49.96M 46.66M 42.56M 79.85M 5.42B 81.19M 564M 219M 2.76B 211M 207M 8.89B
Net Debt -509M -75.94M -67.42M -62.98M -57.44M -108M -7.31B -110M -762M -295M -3.73B -285M -279M -12B -838M -125M -111M -104M -94.63M -178M -12.05B -181M -1.25B -486M -6.14B -470M -459M -19.78B
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
26-09-30 CN¥3.650 +5.19% 353,814,507
26-09-29 CN¥3.470 +0.58% 190,192,890
26-09-28 CN¥3.450 -1.43% 155,925,393
26-09-24 CN¥3.500 -3.85% 184,443,421
26-09-23 CN¥3.640 -3.70% 251,293,444

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002437 Stock